Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JAK inhibitors
Biotech
Soterios looks to ph. 3 after win for alopecia areata cream
Soterios is eyeing phase 3 after a 1% dose of its alopecia areata cream improved severity of the condition, hitting the main goal of a mid-stage test.
James Waldron
May 30, 2024 8:14am
Incyte's oral Dupixent rival hits in midphase skin disease trial
Mar 11, 2024 7:16am
How Takeda beat the rest of the industry to snag Nimbus' TYK2
Jan 11, 2024 10:30am
Aclaris lays off 46%, resurrects zunsemetinib for cancer
Dec 20, 2023 6:09am
ASH: AZ spinout Dizal explores FDA path, US partner for PTCL med
Dec 11, 2023 4:30am
Lynk’s JAK1 inhibitor improves severity, itching in eczema study
Aug 9, 2023 12:35pm